RxDoctor Payments Data

Smita Padala, MD

Nephrology · Lecanto, FLNPI 1790942555

Payments from drug & device makers

$101,547in general payments, 2019–2025

Across 18 payments — averaging $5641.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$60K
  • AbbVie$41K
  • Otsuka America Pharmaceutical, Inc.$162
  • Nuwellis, Inc.$102
  • AstraZeneca$100
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$98
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$23750%
  • Education$23950%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,547 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$241,600
Medicare patients
643
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan32$608,914
FarxigaDapagliflozin Propanediol100$92,726
JardianceEmpagliflozin59$44,102
EntrestoSacubitril/Valsartan14$22,974
VeltassaPatiromer Calcium Sorbitex14$17,920
LokelmaSodium Zirconium Cyclosilicate25$14,577
SpsSodium Polystyrene Sulfon/Sorb17$8,903
Calcitriol377$6,551
Potassium Citrate ErPotassium Citrate49$6,309
Midodrine Hcl78$3,661
Telmisartan84$2,444
Bumetanide61$2,390
Sevelamer Carbonate33$2,348
Hydralazine Hcl151$2,294
Allopurinol324$2,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$162$608,91432 claims
AstraZenecaFarxiga, Lokelma$100$107,303125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Lecanto

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →